BACKGROUND: Brain tumor patients have an increased risk of venous thromboembolism (VTE). An important role in cancer-related VTE has been suggested for tissue factor (TF), the main initiator of the coagulation cascade. We conducted a prospective cohort study to determine whether expression levels of TF in brain tumors are associated with future VTE. PATIENTS AND METHODS: We immunohistochemically determined TF-expression in brain tumor specimens of 96 adult patients (8 low-grade and 82 high-grade gliomas, 6 embryonal tumors) that were included in the Vienna Cancer and Thrombosis Study (CATS). Each patient was prospectively followed until the occurrence of VTE and/or death within a period of two years or loss of follow-up. RESULTS: Fifteen brain tumor patients (15.6%) developed VTE during follow-up. Seventy-seven brain tumors (80.2%) stained positive for TF. Staining was strong in 13 (13.5%), moderate in 64 (66.7%) and negative in 19 (19.8%) tumors. No statistically significant association between TF-expression (negative, focal, widespread) and the occurrence of VTE was found. The hazard ratio (HR) for VTE was 1.30 (95% confidence interval [CI]: 054 - 3.14, p=0.567) when patients with negative-, focal- and widespread TF expression were compared and not statistically significant. Also when tumors were categorized into two groups (focal/widespread versus negative TF-expression), the HR for future VTE was not statistically significant (HR: 1.45, 95% CI: 0.44 - 7.37; p=0.578). An association can still not be definitely excluded, as this study was underpowered. CONCLUSIONS: Our data indicate that TF-expression levels in brain tumors are not strongly associated with future VTE.
BACKGROUND:Brain tumorpatients have an increased risk of venous thromboembolism (VTE). An important role in cancer-related VTE has been suggested for tissue factor (TF), the main initiator of the coagulation cascade. We conducted a prospective cohort study to determine whether expression levels of TF in brain tumors are associated with future VTE. PATIENTS AND METHODS: We immunohistochemically determined TF-expression in brain tumor specimens of 96 adult patients (8 low-grade and 82 high-grade gliomas, 6 embryonal tumors) that were included in the Vienna Cancer and Thrombosis Study (CATS). Each patient was prospectively followed until the occurrence of VTE and/or death within a period of two years or loss of follow-up. RESULTS: Fifteen brain tumorpatients (15.6%) developed VTE during follow-up. Seventy-seven brain tumors (80.2%) stained positive for TF. Staining was strong in 13 (13.5%), moderate in 64 (66.7%) and negative in 19 (19.8%) tumors. No statistically significant association between TF-expression (negative, focal, widespread) and the occurrence of VTE was found. The hazard ratio (HR) for VTE was 1.30 (95% confidence interval [CI]: 054 - 3.14, p=0.567) when patients with negative-, focal- and widespread TF expression were compared and not statistically significant. Also when tumors were categorized into two groups (focal/widespread versus negative TF-expression), the HR for future VTE was not statistically significant (HR: 1.45, 95% CI: 0.44 - 7.37; p=0.578). An association can still not be definitely excluded, as this study was underpowered. CONCLUSIONS: Our data indicate that TF-expression levels in brain tumors are not strongly associated with future VTE.
Authors: Nadim Tawil; Rayhaan Bassawon; Brian Meehan; Ali Nehme; Laura Montermini; Tenzin Gayden; Nicolas De Jay; Cristiana Spinelli; Shilpa Chennakrishnaiah; Dongsic Choi; Lata Adnani; Michele Zeinieh; Nada Jabado; Claudia L Kleinman; Michael Witcher; Yasser Riazalhosseini; Nigel S Key; David Schiff; Steven P Grover; Nigel Mackman; Charles P Couturier; Kevin Petrecca; Mario L Suvà; Anoop Patel; Itay Tirosh; Hamed Najafabadi; Janusz Rak Journal: Blood Adv Date: 2021-03-23
Authors: J E Geddings; Y Hisada; Y Boulaftali; T M Getz; M Whelihan; R Fuentes; R Dee; B C Cooley; N S Key; A S Wolberg; W Bergmeier; N Mackman Journal: J Thromb Haemost Date: 2015-12-11 Impact factor: 5.824
Authors: Shlomit Yust-Katz; Jacob J Mandel; Jimin Wu; Ying Yuan; Courtney Webre; Tushar A Pawar; Harshad S Lhadha; Mark R Gilbert; Terri S Armstrong Journal: J Neurooncol Date: 2015-05-19 Impact factor: 4.130
Authors: Dusten Unruh; Steven R Schwarze; Laith Khoury; Cheddhi Thomas; Meijing Wu; Li Chen; Rui Chen; Yinxing Liu; Margaret A Schwartz; Christina Amidei; Priya Kumthekar; Carolina G Benjamin; Kristine Song; Caleb Dawson; Joanne M Rispoli; Girish Fatterpekar; John G Golfinos; Douglas Kondziolka; Matthias Karajannis; Donato Pacione; David Zagzag; Thomas McIntyre; Matija Snuderl; Craig Horbinski Journal: Acta Neuropathol Date: 2016-09-23 Impact factor: 17.088
Authors: Robson Q Monteiro; Luize G Lima; Nathália P Gonçalves; Mayara R Arruda DE Souza; Ana C Leal; Marcos A Almeida Demasi; Mari C Sogayar; Tatiana C Carneiro-Lobo Journal: Oncol Lett Date: 2016-05-17 Impact factor: 2.967
Authors: Gabriela Cesarman-Maus; Esteban Braggio; Carmen Lome-Maldonado; Ana Lilia Morales-Leyte; Rafael Fonseca Journal: Thromb Res Date: 2014-01-23 Impact factor: 3.944
Authors: Adrian Lee; Malmaruha Arasaratnam; David Lok Hang Chan; Mustafa Khasraw; Viive M Howell; Helen Wheeler Journal: Cochrane Database Syst Rev Date: 2020-05-12